MK-2206, and AZD5363, two inhibitors of AKT, exhibited promising activity against breast cancer cells in preclinical studies (Crafter et al., 2015; Ribas et al., 2015; Choi et al., 2016; Baek et al., 2018; Chen et al., 2018). This evidence concerns the gene AKT1 and breast cancer.